Akari Therapeutics (AKTX) Other Non-Current Assets (2015 - 2026)
Akari Therapeutics recorded quarterly Other Non-Current Assets of $60000.0 in Q1 2026, little changed quarter-over-quarter from $60000.0 in Q4 2025, and down 97.73% year-over-year from $2.6 million in Q1 2025.
Akari Therapeutics' Other Non-Current Assets history runs 10 years deep, the most recent figure standing at $60000.0 for Q1 2026.
- In Q1 2026, Other Non-Current Assets fell 97.73% year-over-year to $60000.0; the TTM figure through Mar 2026 stood at $60000.0 (down 97.73% YoY), while the FY2025 annual figure was $60000.0, down 97.74% from the prior year.
- Other Non-Current Assets came in at $60000.0 for Q1 2026 at Akari Therapeutics, roughly flat from $60000.0 in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $4.2 million in Q2 2024 to a low of $60000.0 in Q2 2025.
- A 5-year average of $1.3 million and a median of $832283.0 in 2023 frame the typical range for Other Non-Current Assets.
- Across the five-year window, Other Non-Current Assets jumped 401.87% in 2024 and tumbled 98.56% in 2025, its largest moves.
- Akari Therapeutics' Other Non-Current Assets stood at $581667.0 in 2022, then surged by 43.09% to $832283.0 in 2023, then soared by 219.48% to $2.7 million in 2024, then plunged by 97.74% to $60000.0 in 2025, then changed by 0.0% to $60000.0 in 2026.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $60000.0, $60000.0, and $60000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 12.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 60,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.26 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 2.13 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 63.55 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | 4.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 60,000.00 |
| Dec 31, 2025 | 5.26 Mn |
| Sep 30, 2025 | 60,000.00 |
| Jun 30, 2025 | 2.77 Mn |
| Mar 31, 2025 | 60,000.00 |
| Dec 31, 2024 | 60,000.00 |
| Sep 30, 2024 | 2.25 Mn |
| Jun 30, 2024 | 4.18 Mn |
| Mar 31, 2024 | 1.31 Mn |
| Dec 31, 2023 | 3.85 Mn |
| Jun 30, 2023 | 832,283.00 |
| Dec 31, 2022 | 581,667.00 |
| Jun 30, 2019 | 17,364.00 |
| Mar 31, 2019 | 147,924.00 |
| Dec 31, 2018 | 521,829.00 |
| Dec 31, 2017 | 142,235.00 |
| Dec 31, 2016 | 142,168.00 |
| Mar 31, 2016 | 142,079.00 |
| Dec 31, 2015 | 142,079.00 |
| Sep 30, 2015 | 142,079.00 |